Iovance Biotherapeutics, Inc.
NASDAQ:IOVA · NASDAQ Global Market
-$0.04 today
Vol 17.40M · Avg 14.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-56.0%
avg -52.0%
ROIC
-51.5%
avg -48.9%
ROA
-42.8%
avg -43.4%
Analysis
ROA is currently the strongest return metric at -42.8% versus its period average of -43.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Frederick G. Vogt | Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director | $1.13M | — | 52 | $109,382.00 | 0.03% |
Raj K. Puri | Chief Regulatory Officer | $867,158.00 | — | 70 | $251,957.00 | 0.07% |
Daniel G. Kirby | Chief Commercial Officer | $804,031.00 | — | 54 | $149,381.00 | 0.04% |
Friedrich Graf Finckenstein | Chief Medical Officer | $764,634.00 | — | 59 | $140,111.00 | 0.04% |
Igor Bilinsky | Chief Operating Officer | $738,374.00 | — | 53 | $137,896.00 | 0.04% |
Corleen Roche | Chief Financial Officer | $494,150.00 | — | 60 | $132,200.00 | 0.04% |
Elma S. Hawkins | Advisor to the Board | $465,395.00 | — | 69 | $275,000.00 | 0.08% |
Brian Gastman | Executive Vice President of Medical Affairs | — | — | — | — | — |
Sara Pellegrino | Senior Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Howard Johnson | Chief Business Officer | — | — | 66 | — | — |
Kevin Smyth | Executive Vice President of Quality | — | — | — | — | — |
Tracy Winton | Executive Vice President of Human Resources | — | — | — | — | — |
Matthew W. Rosinack | Principal Accounting Officer | — | — | 54 | $89,129.00 | 0.02% |
Marc R. Theoret | Senior Vice President of Regulatory Strategy | — | — | — | — | — |
Brian Shew | Senior Vice President & Head of Digital and Information Technology | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.32B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.53B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.47B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.42B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.37B
MeiraGTx Holdings plc
NASDAQ:MGTX
$1.02B
Replimune Group, Inc.
NASDAQ:REPL
$833.91M
Astria Therapeutics, Inc.
ATXS
$718.13M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$580.92M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$472.82M
Who manages IOVA?
Iovance Biotherapeutics, Inc. (IOVA) lists 15 active executives. The top listed executive is Brian Gastman, Executive Vice President of Medical Affairs.
Are IOVA insiders buying or selling?
Recent insider activity shows net selling of $1.72M.
Explore More
Continue the stock analysis
Jump to another research area for this company.